Voyager Therapeutics, Inc. Common Stock VYGR
i
Market datapartial · fetched 2026-11-13T18:52:53.442Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-04-16
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:51:38.28304031Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T18:52:51.518699+00:00
Voyager Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.37 | 383.9% | 65.0% | |||
| 25Δ | 3.62 | 363.3% | 59.3% | |||
| 30Δ | 3.87 | 342.7% | 53.5% | |||
| 35Δ | 4.13 | 322.0% | 47.8% | |||
| 40Δ | 4.38 | 301.4% | 42.0% | |||
| 45Δ | 4.64 | 280.8% | 36.3% | |||
| 50Δ | 4.89 | 260.1% | 30.5% | |||
| 55Δ | 5.14 | 239.5% | 24.8% | |||
| 60Δ | 5.40 | 218.9% | 19.0% | |||
| 65Δ | 5.65 | 198.3% | 13.3% | |||
| 70Δ | 5.90 | 177.6% | 7.5% | |||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.37
- IV
- 383.9%
- B/E move
- 65.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.62
- IV
- 363.3%
- B/E move
- 59.3%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.87
- IV
- 342.7%
- B/E move
- 53.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.13
- IV
- 322.0%
- B/E move
- 47.8%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.38
- IV
- 301.4%
- B/E move
- 42.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.64
- IV
- 280.8%
- B/E move
- 36.3%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.89
- IV
- 260.1%
- B/E move
- 30.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.14
- IV
- 239.5%
- B/E move
- 24.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.40
- IV
- 218.9%
- B/E move
- 19.0%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.65
- IV
- 198.3%
- B/E move
- 13.3%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.90
- IV
- 177.6%
- B/E move
- 7.5%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
WHWK
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in…
More →WVE
Description unavailable
More →XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in…
More →XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company…
More →XFOR
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back…
More →XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients…
More →